Doxazosin

CAS Number74191-85-8
Molecular FormulaC23H25N5O5
Molecular Weight451.5
InChI KeyRUZYUOTYCVRMRZ-UHFFFAOYSA-N
LogP2.5
Synonyms
  • doxazosin
  • 74191-85-8
  • Doxazosine
  • Doxazosina
  • Doxazosinum
  • UK-33274
  • 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
  • UK 33274
  • 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
  • C02CA04
  • NW1291F1W8
  • CHEBI:4708
  • DTXSID7022964
  • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-
  • 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
  • (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHANONE
  • (4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydro-1,4-benzodioxin-2-yl)methanone
  • ratio Doxazosin
  • ratio-Doxazosin
  • DoxaUro
  • Doxazosin Wolff
  • Novo Doxazosin
  • Apo Doxazosin
  • Gen Doxazosin
  • Doxa Puren
  • MTW Doxazosin
  • Neo, Carduran
  • [4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](2,3-dihydro-1,4-benzodioxin-2-yl)methanone
  • 2-(4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazin-1-yl)-6,7-dimethoxyquinazolin-4-amine
  • 2-(4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl)-6,7-dimethoxy-3,4-dihydroquinazolin-4-imine
  • 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxy-3,4-dihydroquinazolin-4-imine
  • Doxazosin ratiopharm
  • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-
  • Ct, Doxazosin Von
  • Von Ct, Doxazosin
  • Doxazosina Ratiopharm
  • Ratiopharm, Doxazosina
  • RefChem:5778
  • Monohydrochloride, Doxazosin
  • DTXCID402964
  • UK33274
  • 616-059-6
  • Doxazosin (INN)
  • C23H25N5O5
  • (RS)-2-{4-[(2,3-Dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
  • [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
  • (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone
  • Doxazosine [French]
  • Doxazosinum [Latin]
  • DOXAZOSIN [INN]
  • Doxazosina [Spanish]
  • Doxazosin [INN:BAN]
  • Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-2-yl)-
  • Cardura XL (TN)
  • supress
  • UNII-NW1291F1W8
  • METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)-
  • 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
  • CPD000097306
  • DOXAZOSIN [MI]
  • Prestwick0_000858
  • Prestwick1_000858
  • Prestwick2_000858
  • Prestwick3_000858
  • DOXAZOSIN [VANDF]
  • ChemDiv2_005017
  • CHEMBL707
  • EC 616-059-6
  • DOXAZOSIN [WHO-DD]
  • (+/-)-DOXAZOSIN
  • 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
  • Lopac0_000474
  • Oprea1_259518
  • SCHEMBL34111
  • BSPBio_000875
  • SPBio_002796
  • BPBio1_000963
  • GTPL7170
  • orb1306007
  • SCHEMBL29641831
  • SCHEMBL29688095
  • BDBM86731
  • HMS1383E01
  • HMS2090C20
  • HMS3259N21
  • HMS3372L09
  • HMS3886J03
  • HMS5085L07
  • HY-B0098
  • ZCA19185
  • EBC-00685
  • MFCD00800482
  • NSC768144
  • NSC768145
  • s5782
  • AKOS001681453
  • AKOS017343634
  • CCG-118218
  • CS-1831
  • DB00590
  • NC00685
  • NSC-768144
  • NSC-768145
  • SDCCGSBI-0050459.P003
  • IDI1_003732
  • NCGC00018158-02
  • NCGC00018158-03
  • NCGC00018158-05
  • NCGC00018158-06
  • NCGC00018158-08
  • NCGC00018158-11
  • NCGC00018158-20
  • NCGC00089775-02
  • [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
  • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine
  • 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
  • AC-11062
  • AC-37660
  • AS-77104
  • SBI-0050459.P002
  • CAS_74191-85-8
  • DB-055848
  • UK 33,274
  • NS00000605
  • UK-3327427
  • EN300-53055
  • C06970
  • D07874
  • T22316
  • F800437
  • L000738
  • Q419939
  • BRD-A13188892-066-03-3
  • BRD-A13188892-066-13-2
  • BRD-A13188892-066-21-5
  • BRD-A13188892-066-22-3
  • 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL)PIPERAZINE
  • 137888-77-8

Applications:

HPLC Chiral Separation of Doxazosin Enantiomers on Cyralis CM Column

July 13, 2026

HPLC Method for Analysis of Doxazosin on Cyralis CM Column by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Doxazosin.

Doxazosin is a medication with the chemical formula C23H25N5O5. It is used to treat symptoms of of post-traumatic stress disorder, hypertension, and benign prostatic hyperplasia. It works as an alpha-1 blocker and a1-adrenergic receptor antagonist.

This application describes a normal-phase chiral HPLC method for the separation of Doxazosin enantiomers using SIELC’s Cyralis CM chiral column. Cyralis CM is a cellulose-based chiral stationary phase (CSP) designed for enantiomeric separations, optical purity testing, chiral impurity analysis, and stereoisomer characterization in pharmaceutical, chemical, agrochemical, and fine chemical applications. For best results, the sample should be prepared fresh for analysis.

Doxazosin can be retained and analyzed using the Cyralis CM stationary phase column. The analysis utilizes an isocratic method with a mobile phase consisting of Hexane, IPA, and 2-(dimethylamino)ethanol. Detection is performed using UV.

Condition

ColumnCyralis CM, 4.6 x 100 mm, 5 µm, 100 A, dual ended
Mobile PhaseHexane/Ethanol/2-(dimethylamino)ethanol
Flow Rate1.0 mL/min
DetectionUV 270 nm
Resolution1.51

Description

Class of CompoundsDrug
Analyzing CompoundsDoxazosin

Application Column

Cyralis CM

Column Diameter: 4.6 mm
Column Length: 100 mm
Particle Size: 5 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Doxazosin
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.